Management of premature ovarian insufficiency

被引：0

作者：

Weidlinger S. ^{[1
]}

Stute P. ^{[1
]}

机构：

[1] Abteilung für Gynäkologische Endokrinologie und Reproduktionsmedizin, Universitätsklinik für Frauenheilkunde, Inselspital Bern, Effingerstr. 102, Bern

来源：

Gynäkologische Endokrinologie | 2018年 / 16卷 / 4期

关键词：

Cardiovascular diseases; Hormone replacement therapy; Osteoporosis; Premature ovarian insufficiency; Primary prevention;

D O I：

10.1007/s10304-018-0201-3

中图分类号：

学科分类号：

摘要：

The term “premature ovarian insufficiency” (POI) describes the premature loss of ovarian function before the age of 40 years. With POI comes a combination of hypogonadotropic hypogonadism and primary/secondary amenorrhea. POI not only has an adverse impact on a woman’s quality of life, psychological well-being and fertility, but is also associated with negative long-term effects on bone health, cardiovascular system and cognitive function. To prevent estrogen deficiency-related long-term consequences hormone replacements therapy at least until the average natural menopause age is recommended. The benefit-risk profile of HRT in naturally postmenopausal women cannot be unrestrictedly extrapolated to the cohort of patients with POI. In patients with POI, the benefits of HRT far outweigh the potential risks. © 2018, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

引用

页码：254 / 260

页数：6

共 25 条

[1]

Hamoda H., The British menopause society and women’s health concern recommendations on the management of women with premature ovarian insufficiency, Post Reprod Health, 23, 1, pp. 22-35, (2017)

[2]

Roeters van Lennep J.E., Et al., Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis, Eur J Prev Cardiol, 23, 2, pp. 178-186, (2016)

[3]

Archer D.F., Premature menopause increases cardiovascular risk, Climacteric, 12, pp. 26-31, (2009)

[4]

Kalantaridou S.N., Et al., Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy, J Clin Endocrinol Metab, 89, 8, pp. 3907-3913, (2004)

[5]

ESHRE Guideline: management of women with premature ovarian insufficiency, Hum Reprod, 31, 5, pp. 926-937, (2016)

[6]

Kanis J.A., Et al., A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation, Arch Osteoporos, 11, 1, (2016)

[7]

Popat V.B., Et al., Bone mineral density in estrogen-deficient young women, J Clin Endocrinol Metab, 94, 7, pp. 2277-2283, (2009)

[8]

Bachelot A., Et al., Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure, Eur J Endocrinol, 161, 1, pp. 179-187, (2009)

[9]

Crofton P.M., Et al., Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover, Clin Endocrinol (oxf), 73, 6, pp. 707-714, (2010)

[10]

Cartwright B., Et al., Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on Bone mineral density, J Clin Endocrinol Metab, 101, 9, pp. 3497-3505, (2016)

← 1 2 3 →